X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2443) 2443
Book Review (847) 847
Patent (799) 799
Publication (203) 203
Conference Proceeding (34) 34
Dissertation (21) 21
Book Chapter (16) 16
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2014) 2014
humans (1884) 1884
oncology (1463) 1463
female (993) 993
single-agent (801) 801
chemotherapy (771) 771
chemistry (768) 768
metallurgy (765) 765
middle aged (765) 765
aged (741) 741
male (696) 696
performing operations (652) 652
transporting (652) 652
adult (650) 650
antineoplastic combined chemotherapy protocols - therapeutic use (601) 601
treatment outcome (527) 527
dressing or conditioning of abrading surfaces (508) 508
feeding of grinding, polishing, or lapping agents (508) 508
grinding (508) 508
machines, devices, or processes for grinding or polishing (508) 508
polishing (508) 508
cancer (496) 496
antineoplastic agents - therapeutic use (482) 482
phase-ii trial (421) 421
electricity (397) 397
basic electric elements (393) 393
apparatus therefor (380) 380
after-treatment of single crystals or a homogeneouspolycrystalline material with defined structure (374) 374
crystal growth (374) 374
production of a homogeneous polycrystalline material withdefined structure (374) 374
refining by zone-melting of material (374) 374
single crystals or homogeneous polycrystalline material withdefined structure (374) 374
single-crystal-growth (374) 374
unidirectional solidification of eutectic material orunidirectional demixing of eutectoid material (374) 374
animal and vegetable oils, fats, fatty substances and waxes (363) 363
candles (363) 363
detergent compositions (363) 363
detergents (363) 363
electric solid state devices not otherwise provided for (363) 363
fatty acids therefrom (363) 363
recovery of glycerol (363) 363
resin soaps (363) 363
semiconductor devices (363) 363
soap or soap-making (363) 363
use of single substances as detergents (363) 363
hematology (361) 361
adhesives (302) 302
dyes (302) 302
miscellaneous applications of materials (302) 302
miscellaneous compositions (302) 302
natural resins (302) 302
paints (302) 302
polishes (302) 302
care and treatment (281) 281
human necessities (275) 275
pharmacology & pharmacy (270) 270
aged, 80 and over (266) 266
materials for miscellaneous applications, not provided forelsewhere (261) 261
lung neoplasms - drug therapy (255) 255
chemical materials for use in breathing apparatus (252) 252
chemical means for extinguishing fires or for combating orprotecting against harmful chemical agents (252) 252
fire-fighting (252) 252
life-saving (252) 252
gemcitabine (250) 250
deoxycytidine - analogs & derivatives (249) 249
therapy (249) 249
cisplatin (235) 235
phase-ii (235) 235
antineoplastic combined chemotherapy protocols - adverse effects (234) 234
carcinoma, non-small-cell lung - drug therapy (234) 234
prognosis (225) 225
disease-free survival (222) 222
neoplasm staging (216) 216
combination (213) 213
single-agent bevacizumab (208) 208
trial (208) 208
open-label (207) 207
research (206) 206
drug therapy (205) 205
survival (202) 202
paclitaxel (194) 194
survival analysis (193) 193
breast neoplasms - drug therapy (189) 189
medicine & public health (188) 188
deoxycytidine - administration & dosage (187) 187
hematology, oncology and palliative medicine (187) 187
single-agent gemcitabine (187) 187
animals (185) 185
combination chemotherapy (185) 185
randomized-trial (184) 184
drug administration schedule (180) 180
bevacizumab (178) 178
clinical trials as topic (174) 174
antineoplastic agents - adverse effects (169) 169
single-agent carfilzomib (168) 168
compositions based thereon (164) 164
organic macromolecular compounds (164) 164
their preparation or chemical working-up (164) 164
survival rate (160) 160
bortezomib (158) 158
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2765) 2765
Chinese (598) 598
Japanese (419) 419
French (101) 101
German (23) 23
Spanish (5) 5
Korean (2) 2
Italian (1) 1
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Single-Agent Therapy for Low Risk Gestational Trophoblastic Neoplasia (LRGTN): A Preliminary Report on a Randomized Clinical Trial to Compare Pulse-Methotrexate versus Pulse-Dactinomycin, 12/2004
The efficacy of single-agent chemotherapy for patients with low risk gestational trophoblastic neoplasia (LRGTN) with methotrexate or dactinomycin is well... 
Gestational trophoblastic neoplasia, Single-agent chemotherapy, Methotrexate, Dactinomycin
Journal
LANCET, ISSN 0140-6736, 02/2016, Volume 387, Issue 10020, pp. 770 - 778
Background Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in... 
MEDICINE, GENERAL & INTERNAL | MALIGNANCY | BRUTON TYROSINE KINASE | SINGLE-AGENT TEMSIROLIMUS | RESPONSE CRITERIA | GUIDELINES | PCI-32765 | BTK | CHRONIC LYMPHOCYTIC-LEUKEMIA | FOLLOW-UP | BORTEZOMIB
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 10/2008, Volume 26, Issue 28, pp. 4617 - 4625
Purpose Since our individual patient data (IPD) meta-analysis (MA) of supportive care and chemotherapy for non -small-cell lung cancer (NSCLC), published in... 
SINGLE-AGENT | PLUS CHEMOTHERAPY | MULTICENTER | ETOPOSIDE | CISPLATIN | ONCOLOGY | STATISTICS | PHASE-III | COMBINATION CHEMOTHERAPY | QUALITY-OF-LIFE | CARCINOMA
Journal Article
BLOOD, ISSN 0006-4971, 03/2016, Volume 127, Issue 11, pp. 1502 - 1508
The cumulative incidence of National Institutes of Health (NH-)-defined chronic graft versus -host disease (GVHD) requiring systemic treatment is 35% at 1 year... 
MORTALITY | SINGLE-AGENT | PROPHYLAXIS | DIAGNOSIS | STEM-CELLS | BONE-MARROW-TRANSPLANTATION | PILOT PHARMACOLOGICAL BIOMARKER | RECIPIENTS | HEMATOLOGY | FLUDARABINE | BUSULFAN
Journal Article
Blood, ISSN 0006-4971, 02/2018, Volume 131, Issue 8, pp. 855 - 863
Novel therapies are needed for patients with relapsed or refractory multiple myeloma (MM). We conducted a multicenter, phase 1 study in advanced hematological... 
DARATUMUMAB | SINGLE-AGENT | DEXAMETHASONE | CARFILZOMIB | NUCLEAR EXPORT | OPEN-LABEL | PHASE-2 | XPO1/CRM1 | INHIBITOR | HEMATOLOGY | POMALIDOMIDE | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 2, pp. 142 - 152
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 02/2017, Volume 15, Issue 2, pp. 230 - 230
Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal... 
SINGLE-AGENT CARFILZOMIB | INTERGROUPE FRANCOPHONE | DONOR LYMPHOCYTE INFUSIONS | INDUCTION THERAPY | ONCOLOGY | BORTEZOMIB PLUS DEXAMETHASONE | HIGH-DOSE THERAPY | INTERNATIONAL STAGING SYSTEM | TERM-FOLLOW-UP | STEM-CELL TRANSPLANTATION | LENALIDOMIDE MAINTENANCE
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 13, pp. 1302 - 1308
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. e395 - e403
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2019, Volume 25, Issue 2, pp. 496 - 505
Purpose: This study examined safety, pharmacokinetics, and efficacy of veliparib, a PARP inhibitor, combined with carboplatin and etoposide in patients with... 
TRIAL | SINGLE-AGENT | GERMLINE BRCA1 | ONCOLOGY | ABT-888 | PLUS CARBOPLATIN | OVARIAN-CANCER | DNA-REPAIR | COMBINATION | CHEMOTHERAPY | PARP INHIBITOR VELIPARIB
Journal Article
International Journal of Clinical Oncology, ISSN 1341-9625, 2/2018, Volume 23, Issue 1, pp. 1 - 34
Journal Article